SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

26 Oct 2021 Evaluate
A minor change in the total revenue was seen in the September 2021 quarter. The total revenue for the quarter stood at Rs. 39350.30 millions against Rs. 38078.90 millions during year ago period.Profit for the quarter ended September 2021 increased merely by4.93% to Rs. 7823.70  millions from Rs. 7456.40 millions.Operating profit surged to 11805.50 millions from the corresponding previous quarter of 11701.40 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 39350.30 38078.90 3.34 79524.40 69359.10 14.66 139005.80 126591.50 9.81
Other Income 1977.30 391.70 404.80 2773.90 848.30 227.00 2302.80 8928.50 -74.21
PBIDT 11805.50 11701.40 0.89 24057.00 21605.40 11.35 39518.40 36001.40 9.77
Interest 76.00 116.90 -34.99 156.00 259.00 -39.77 450.70 360.50 25.02
PBDT 11729.50 11584.50 1.25 23901.00 21346.40 11.97 39067.70 35640.90 9.61
Depreciation 1389.70 1408.00 -1.30 2759.50 2845.30 -3.02 5561.10 5997.80 -7.28
PBT 10339.80 10176.50 1.60 21141.50 18501.10 14.27 33506.60 29643.10 13.03
TAX 2516.10 2720.10 -7.50 5400.10 4941.70 9.28 8823.80 6461.40 36.56
Deferred Tax 30.20 -96.50 -131.30 -117.30 -259.30 -54.76 -220.00 1001.80 -121.96
PAT 7823.70 7456.40 4.93 15741.40 13559.40 16.09 24682.80 23181.70 6.48
Equity 1613.30 1612.70 0.04 1613.30 1612.70 0.04 1612.90 1612.50 0.02
PBIDTM(%) 30.00 30.73 -2.37 30.25 31.15 -2.89 28.43 28.44 -0.03

Cipla Share Price

1232.90 4.00 (0.33%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×